Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of CERC-501, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 8
- 试验地点
- 4
- 主要终点
- Change in Hamilton Rating Scale for Depression - 6 Items (HAM-D-6)
研究概览
简要总结
This study is looking at the efficacy, rapidity, safety, and tolerability of two doses of oral CERC-501 for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.
详细描述
This study will involve 10 visits to the clinical site over approximately 1.5 months. There will be a screening visit (7-28 days may pass between the screening visit and the first treatment visit), a baseline/treatment visit (first day of study drug treatment), followed by 5 consecutive days of treatment visits. Follow-up visits will occur 6, 13, and 20 days after first receiving study drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, 18-65 years old.
- •Able to read, understand, and provide written, dated informed consent prior to screening.
- •Diagnosed with Major Depressive Disorder (MDD), single or recurrent, and currently experiencing a Major Depressive Episode (MDE) of at least eight weeks in duration, prior to screening.
- •Has a history of treatment resistance during the current MDE.
- •Meet the threshold on the total MADRS score of greater than or equal to 20 at both screening and baseline visits, as confirmed by the remote centralized MGH CTNI rater between the screen visit and the baseline visit.
- •In good general health
- •For female participants, status of non-childbearing potential or use of an acceptable form of birth control
- •Body mass index between 18-40 kg/m2
- •Concurrent psychotherapy will be allowed if the type and frequency of the therapy has been stable for at least three months prior to screening and is expected to remain stable during participation in the study
- •Concurrent benzodiazepine and hypnotic therapy will be allowed if the therapy has been stable for at least 4 weeks prior to screening and if it is expected to remain stable during the course of the subject's participation in the study.
排除标准
- •Female of childbearing potential who is not willing to use one of the specified forms of birth control during the study
- •Female that is pregnant or breastfeeding
- •Female with a positive pregnancy test at screening or baseline
- •History during the current MDE of failure to achieve a satisfactory response to >3 treatment courses of a therapeutic dose of an antidepressant therapy of at least 8 weeks duration during the current episode
- •Total MADRS score of <20 at the screen or baseline visits, or as assessed by the remote, independent MGH CTNI rater and reported to the site
- •Current diagnosis of a Substance Use Disorder (Abuse or Dependence) with the exception of nicotine dependence, at screening or within six months prior to screening
- •Current diagnosis of Axis I disorders other than Dysthymic Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder or Specific Phobia (unless one of these is comorbid and clinically unstable, and/or the focus of the participant's treatment for the past 6 months or more)
- •History of bipolar disorder, schizophrenia or schizoaffective disorders, or any history of psychotic symptoms in the current or previous depressive episodes
- •History of eating disorders within five years of screening
- •Any Axis I or Axis II Disorder, which at screening is clinically predominant to their MDD or has been predominant at any time within 6 months prior to screening
- •Subject is considered at significant risk for suicidal behavior during the course of their participation in the study
- •Subject has had electroconvulsive therapy in the current episode of depression
- •Has received vagus nerve stimulation (VNS) at any time prior to screening
- •Dementia, delirium, amnestic, or any other cognitive disorder
- •Has a clinically significant abnormality on the screening physical examination
- •Participation in any clinical trial with an investigational drug or device within the past month or concurrent to study participation
- •Known history or current episode of: Uncontrolled hypertension, Recent myocardial infarction (within one year) or a history of more than one myocardial infarction, Syncopal event within the past year, Congestive heart failure, Angina pectoris, Systolic BP <85 or >160 mmHg or diastolic BP >95 mmHg or heart rate <50 or >105 beats per minute at screening or randomization, or QTcF greater than or equal to 450 msec at screening or randomization.
- •Chronic lung disease
- •Lifetime history of surgical procedures involving the brain or meninges, encephalitis, meningitis, degenerative central nervous system disorder, epilepsy, mental retardation, or any other disease/procedure/accident/intervention associated with significant injury to or malfunction of the central nervous system, or a history of significant head trauma within the past 2 years
- •Presents with a history of Thyroid stimulating hormone outside of the normal limits and clinically significant as determined by the investigator
- •Patients with diabetes mellitus fulfilling any of the following criteria:
- •Unstable diabetes mellitus defined as glycosylated hemoglobin (HbA1c) >8.5% at screening
- •Admitted to hospital for treatment of diabetes mellitus or diabetes mellitus related illness in the past 12 weeks
- •Not under physician care for diabetes mellitus
- •Has not been on the same dose of oral hypoglycaemic drug(s) and/or diet for the 4 weeks prior to screening. For thiazolidinediones (glitazones) this period should not be less than 8 weeks.
- •Any other clinically significant abnormal laboratory result (as determined after evaluation by study investigator and MGH CTNI medical monitor) at the time of the screening exam.
- •History of hypothyroidism and has been on a stable dosage of thyroid replacement medication, or was surgically treated less than six months prior to screening
- •History of hyperthyroidism which was treated (medically or surgically) less than six months prior to screening
- •Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with the interpretation of study results
- •History of positive screening urine test for drugs of abuse
- •Patients with exclusionary laboratory values, or requiring treatment with exclusionary concomitant medications, including tricyclic antidepressants and monoamine oxidase inhibitors, or on two or more concomitant antidepressant therapies
- •Patients currently taking a proton pump inhibitor (PPI)/histamine 2 (H2) blocker or with a history of chronic NSAID use
- •Patients with a positive test for Helicobacter pylori (urea breath test)
- •Patients with any of the following GI-related findings:
- •Clinically evident GI complaints or GI disease at Screening or Visit 1
- •Past history of gastric disease (including but not limited to peptic ulcer disease, gastritis (including atrophic gastritis), upper GI bleeding, any other GI precancerous conditions), and of any other clinically relevant GI disease.
研究组 & 干预措施
Low Dose Drug-Drug Arm
Patients in this arm will receive CERC-501 10.0 mg/day for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
干预措施: CERC-501 (Drug)
High Dose Drug-Drug Arm
Patients in this arm will receive CERC-501 20.0 mg/day for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
干预措施: CERC-501 (Drug)
Placebo/Low-Dose Drug Arm
Patients in this arm will receive placebo for 3 days (in Phase 1) and CERC-501 10.0 mg/day for 3 days (in Phase 2)
干预措施: CERC-501 (Drug)
Placebo/Low-Dose Drug Arm
Patients in this arm will receive placebo for 3 days (in Phase 1) and CERC-501 10.0 mg/day for 3 days (in Phase 2)
干预措施: Placebo (Drug)
Placebo/High-Dose Drug Arm
Patients in this arm will receive placebo for 3 days (in Phase 1) and CERC-501 20.0 mg/day for 3 days (in Phase 2)
干预措施: CERC-501 (Drug)
Placebo/High-Dose Drug Arm
Patients in this arm will receive placebo for 3 days (in Phase 1) and CERC-501 20.0 mg/day for 3 days (in Phase 2)
干预措施: Placebo (Drug)
Placebo/Placebo Arm
Patients in this arm will receive placebo for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
干预措施: Placebo (Drug)
结局指标
主要结局
Change in Hamilton Rating Scale for Depression - 6 Items (HAM-D-6)
时间窗: Baseline and 72 hours after initiating treatment
This instrument is completed with a structured interview guide by the clinician based on his/her assessment of the patient's symptoms. This structured interview has been validated for use with time frames shorter than one week. Scale items are assessed based on symptoms within the past 24 hours. A higher score indicates more depression symptoms. Total scores range from 0 (normal) to 22 (severe). To better estimate the baseline, we did not use simply the cross-sectional assessment at baseline, but we estimated the average during the screening period as the true baseline.
次要结局
- Change in Clinical Global Impression -Severity (CGI-S)(Baseline and 72 hours and 20 days after initiating treatment)
- Clinical Global Impression-Improvement (CGI-I)(72 hours and 20 days after initiating treatment)
- Change in Symptoms of Depression Questionnaire (SDQ)(Baseline and 72 hours and 20 days after initiating treatment)
- Number of Participants With Clinically Significant Abnormal Labs(72 hours after treatment initiation)
- Change in Hamilton Rating Scale for Depression - 6 Items (HAM-D-6), Day 20(Baseline and 20 days after initiating treatment)
- Change in Montgomery-Asberg Depression Rating Scale (MADRS)(Baseline and 72 hours and 20 days after initiating treatment)
- Change in Positive Affect Scale (PAS)(Baseline and 72 hours and 20 days after initiating treatment)
- Change in the Columbia-Suicide Severity Rating Scale (C-SSRS)(Baseline and 72 hours after initiating treatment)
- Number of Participants With Clinically Significant Abnormal ECG(72 hours after treatment initiation)
- Number of Participants With Response on Hamilton Rating Scale for Depression - 6 Items (HAM-D-6)(72 hours after treatment initiation)
- Change in Perceived Stress Scale (PSS)(Baseline and 72 hours and 20 days after treatment initiation)
- Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Satisfaction With Participation in Social Roles and Discretionary Activities(Baseline and 72 hours and 20 days after initiating treatment)
研究者
Maurizio Fava, MD
Overall Principal Investigator
Massachusetts General Hospital